44,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Emerging evidence shows that the prevalence of hypertension is on the rise in most African countries while control remains poor. There are effective interventions which could be implemented in hospitals of low resource setting to improve control of blood pressure among hypertensive patients. The objectives of this study were therefore to calculate the costs, effects, and evaluate the cost-effectiveness of three interventions (i.e. self monitoring, health professional led care and organization driven interventions) that could be implemented in Nigeria s hospitals to ensure continuity of care…mehr

Produktbeschreibung
Emerging evidence shows that the prevalence of hypertension is on the rise in most African countries while control remains poor. There are effective interventions which could be implemented in hospitals of low resource setting to improve control of blood pressure among hypertensive patients. The objectives of this study were therefore to calculate the costs, effects, and evaluate the cost-effectiveness of three interventions (i.e. self monitoring, health professional led care and organization driven interventions) that could be implemented in Nigeria s hospitals to ensure continuity of care and improved control of blood pressure in hypertensive patients. The study employed a decision analytic modelling. Probabilistic cost-effectiveness analysis was performed using Markov Chain Monte Carlo simulation, and presented as cost-effectiveness acceptability curves and frontiers. The result of this study shows that health professional led care through a pharmaceutical care model or nurse led care is the most cost-effective option for ensuring that patients with high blood pressure are adequately followed for better control of blood pressure.
Autorenporträt
Obinna Ikechukwu Ekwunife, is a lecturer in the Department of Clinical Pharmacy and Pharmacy Management, University of Nigeria. Obinna has four years teaching experience in Pharmacotherapeutics and he researches on pharmacoeconomics and outcome research.